These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1615 related items for PubMed ID: 33167919

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, Perez-Peña J, Győrffy B, Ocaña A, Galán-Moya EM.
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ, Liu YY, Li XG, Lian B, Lu XX, Jin X, Shao ZM, Hu X, Di GH, Jiang YZ.
    Cancer Res; 2021 Nov 01; 81(21):5491-5505. PubMed ID: 34408002
    [Abstract] [Full Text] [Related]

  • 8. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC, Hsu HL.
    Mol Cancer; 2019 Mar 18; 18(1):42. PubMed ID: 30885232
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer.
    Wang Y, Zhang Y, Qi X.
    Hum Cell; 2024 Sep 18; 37(5):1475-1488. PubMed ID: 38879857
    [Abstract] [Full Text] [Related]

  • 11. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
    Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B.
    Cancer Lett; 2014 Oct 28; 353(2):153-9. PubMed ID: 25130168
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J, Xue X, Jiang K.
    Curr Mol Med; 2019 Oct 28; 19(2):147-155. PubMed ID: 30854965
    [Abstract] [Full Text] [Related]

  • 13. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Doherty MR, Parvani JG, Tamagno I, Junk DJ, Bryson BL, Cheon HJ, Stark GR, Jackson MW.
    Breast Cancer Res; 2019 Apr 29; 21(1):54. PubMed ID: 31036052
    [Abstract] [Full Text] [Related]

  • 14. A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.
    Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg AL, Carraway KL, Yu A, Sweeney C.
    Cancer Res; 2020 Feb 01; 80(3):418-429. PubMed ID: 31694904
    [Abstract] [Full Text] [Related]

  • 15. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
    Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT.
    Oncogene; 2017 May 04; 36(18):2599-2608. PubMed ID: 27941886
    [Abstract] [Full Text] [Related]

  • 16. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST.
    Breast Cancer Res; 2021 Jun 12; 23(1):65. PubMed ID: 34118960
    [Abstract] [Full Text] [Related]

  • 17. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.
    Cancer Lett; 2017 May 28; 394():52-64. PubMed ID: 28254410
    [Abstract] [Full Text] [Related]

  • 18. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo.
    Castro NP, Rangel MC, Merchant AS, MacKinnon G, Cuttitta F, Salomon DS, Kim YS.
    Cancer Prev Res (Phila); 2019 Mar 28; 12(3):147-158. PubMed ID: 30679159
    [Abstract] [Full Text] [Related]

  • 19. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Hu J, Lai Y, Huang H, Ramakrishnan S, Pan Y, Ma VWS, Cheuk W, So GYK, He Q, Geoffrey Lau C, Zhang L, Cho WCS, Chan KM, Wang X, Rebecca Chin Y.
    Br J Cancer; 2022 Jan 28; 126(1):57-71. PubMed ID: 34718356
    [Abstract] [Full Text] [Related]

  • 20. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, Zhang L, Chen J.
    Mol Cancer; 2020 Apr 07; 19(1):73. PubMed ID: 32264877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.